COMMUNIQUÉS West-GlobeNewswire

Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026
30/06/2026
Multi-omics analyses identifies linoleic acid as a critical fatty acid which is modulated by ART26.12 SOLANA BEACH, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage [...]
Trinity Biotech’s Trinovium Secures Open Compute Project Membership, Advancing Hyperscale Market Access and Commercial Validation for AI Data Center Liquid Cooling
30/06/2026
- Milestone an important step in launching Trinovium within the global AI data center ecosystem - Data center liquid cooling market projected to expand from $4 billion in 2026 to $27 billion by 2033 1 DUBLIN and [...]
Psychemedics Releases 2026 Education Insights Report
30/06/2026
New Report Examines Emerging Student Substance Use Trends and Their Impact on Academic Success, Student Wellness, and Campus Safety DALLAS, June 30, 2026 (GLOBE NEWSWIRE) -- Psychemedics Corporation, the pioneer and [...]
Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease
30/06/2026
WILMETTE, Ill., June 30, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with [...]
MediciNova CEO Provides Shareholder Update
30/06/2026
LA JOLLA, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875 [...]
U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA
30/06/2026
Vafseo ® demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen Primary Investigator to stop trial on recommendation from Independent [...]
Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)
30/06/2026
Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated safety profile for [...]
Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome
30/06/2026
Allowed Claims Cover a Method of Treating Netherton Syndrome with a Topical Serine Protease Inhibitor and an Anti-Inflammatory Agent, Including in Patients with SPINK5 Mutations ASHBURN, Va., June 30, 2026 (GLOBE [...]
LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations
30/06/2026
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar [...]
Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses
30/06/2026
Data Demonstrate Vamorolone’s Balanced Corticosteroid Profile with On-Target Glucocorticoid Activity and Without Evidence of Significant Immunosuppressive Activity at Clinical Doses CORAL GABLES, Fla., June 30, 2026 ( [...]
Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants
30/06/2026
June 30, 2026 Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) (“Biodexa” or the “ [...]
Weight Watchers Med+ Establishes Access to GLP-1s Through Medicare GLP-1 Bridge Program
30/06/2026
Weight Watchers expands access for Med+ Medicare beneficiaries to GLP-1 medications covered by the Medicare Bridge Program. NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight [...]
FEATOL Rolls Out Reinforced Lower Back Brace to Help Adults During Work, Driving, and in Chronic Pain
30/06/2026
The latest adjustable lumbar support from FEATOL combines stability with comfort, providing much-needed mobility support for those experiencing lower back fatigue NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- With more [...]
Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1
30/06/2026
GeneTAC ® small molecule designed to selectively reduce transcription of the mutant DMPK allele and address the underlying cause of DM1 CARLSBAD, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. ( [...]
Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic
30/06/2026
Key U.S. patent now protects exclusivity for developing stenoparib with the stenoparib-DRP ® until April 2042 TARPON SPRINGS, Fla., June 30, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR [...]
Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer
30/06/2026
- Findings provide mechanistic support for previously reported clinical outcomes of clinical reversal of platinum resistance/refractoriness from Phase 2 VIRO-15 trial - - Data demonstrate Olvi-Vec–mediated modulation of [...]
TerrAscend Signs Agreement to Acquire Fifth Dispensary in New Jersey
30/06/2026
Aunt Mary’s, a high-performing dispensary in Hunterdon County, generates over $10 million in annualized revenue Transaction expected to be immediately accretive on an EBITDA and free cash flow basis, further extending [...]
Imviva Biotech Receives FDA IDE Authorization for clonoSEQ® Assay in TENACITY-01 Clinical Trial
30/06/2026
Highly sensitive next-generation sequencing-based MRD testing will identify eligible patients with T-cell malignancies for trial enrollment and precisely evaluate treatment response BOSTON, June 30, 2026 (GLOBE NEWSWIRE [...]
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
30/06/2026
Dose-optimization data from the Phase 1 study expected Q3 2026 to support Phase 2 proof-of-concept initiation in ADPKD in Q4 2026 JERSEY CITY, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a [...]

Pages